Marvin L. White
Known title: DirectorCIK: 0001493324
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
EBS Shares Rise 14.4% After Russia Plague Lab Worker Death. EBS stock jumped 14.4% following the death of a Russian plague laboratory worker, a move that also lifted other vaccine makers such as Novavax, Arcturus and Moderna. The rally has drawn attention from retail traders who are looking for potential contract awards. The shares are currently trading near the $7.98 support level, which has been tested 20 times, and the RSI sits at 55.1, indicating neither overbought nor oversold conditions.
Transaction History
| APVO | ▲ Buy | Option Exercise | 1,666 | — | 8/6/2026 | View on chart |
| APVO | ▼ Sell | Tax Withholding | 406 | $2K | 8/6/2026 | View on chart |
| APVO | ▲ Buy | Option Exercise | 1 | — | 7/17/2026 | View on chart |
| EBS | ▲ Buy | Grant | 25,344 | $0 | 4/30/2026 | View on chart |
| APVO | ▲ Buy | Option Exercise | 10 | — | 7/17/2025 | View on chart |
| EBS | ▲ Buy | Grant | 34,403 | $0 | 4/30/2025 | View on chart |
| APVO | ▲ Buy | Option Exercise | 6 | — | 3/3/2025 | View on chart |
| APVO | ▲ Buy | Option Exercise | 8 | — | 3/2/2025 | View on chart |
| EBS | ▼ Sell | Open Market | 14,287 | $171K | 11/11/2024 | View on chart |
| EBS | ▲ Buy | Grant | 17,430 | $0 | 5/23/2024 | View on chart |
| APVO | ▲ Buy | Option Exercise | 9,584 | — | 3/3/2024 | View on chart |
| APVO | ▲ Buy | Option Exercise | 12,917 | — | 3/2/2024 | View on chart |
| APVO | ▲ Buy | Option Exercise | 4,792 | — | 1/28/2024 | View on chart |
| EBS | ▲ Buy | Grant | 33,847 | $0 | 5/25/2023 | View on chart |
| APVO | ▲ Buy | Option Exercise | 9,582 | — | 3/3/2023 | View on chart |
| APVO | ▲ Buy | Option Exercise | 4,791 | — | 1/29/2023 | View on chart |
| EBS | ▲ Buy | Grant | 8,446 | $0 | 5/26/2022 | View on chart |
| APVO | ▲ Buy | Option Exercise | 4,792 | — | 1/29/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
APVO to Present Multispecific Platform at SITC 2026 Meeting
Aptevo Therapeutics announced it will showcase its multispecific antibody platform at the upcoming SITC 2026 Annual Meeting. The presentation offers the company a chance to highlight its pipeline to a specialized oncology audience. The stock is currently near a support level and has a relatively low RSI, which may reflect recent price pressure.
APVO to Present Multispecific Platform at SITC 2026 Meeting. Aptevo Therapeutics announced it will showcase its multispecific antibody platform at the upcoming SITC 2026 Annual Meeting. The presentation offers the company a chance to highlight its pipeline to a specialized oncology audience. The stock is currently near a support level and has a relatively low RSI, which may reflect recent price pressure.